Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2Glioblastoma 2Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

Temozolomide 109Magnetic Resonance Spectroscopy 52Bevacizumab 52Radiotherapy 44Irinotecan 27Blood Specimen Collection 19Surgical Procedures, Operative 16Radiation 15Aminolevulinic Acid 15Carboplatin 13fluorodopa F 18 12Nivolumab 12Radiotherapy, Intensity-Modulated 11Carmustine 11Radiosurgery 10Magnetic Resonance Imaging 10pembrolizumab 9Topotecan 9Specimen Handling 9Everolimus 9Erlotinib Hydrochloride 9Biopsy 9poly ICLC 8Surveys and Questionnaires 8Standard of Care 8Etoposide 8Drug Therapy 8Lomustine 7Filgrastim 7Cyclophosphamide 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Glioma × azeliragon × Clear all
NCT06724926 2026-05-18

Concurrent Azeliragon With Craniospinal Irradiation

NYU Langone Health

Phase 1 Active not recruiting
21 enrolled
CNS

Glioma, Meningeal Carcinomatosis

NCT05773664 2024-09-19

Dexamethasone and Azeliragon for Management of Post-Resection Cerebral Edema in Patients with Glioblastoma

City of Hope Medical Center

Phase 1 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡